Table 6 Types of chemotherapy of MPM patients between PS and non-PS groupsa
From: Risk factors and prognosis of malignant peritoneal mesothelioma with paraneoplastic syndrome
Variables | Non-PS group (n = 86) | PS group (n = 60) | ||
|---|---|---|---|---|
Preoperative intravenous chemotherapy, n (%) | ||||
PEM + DDP/CBP/NDP/LBP | 35 (40.7) | PEM + DDP/CBP/NDP/OXA/LBP | 24 (40.0) | |
PEM | 4 (4.7) | PTX + DDP/CBP | 5 (8.3) | |
PTX + DDP | 2 (2.3) | GEM + DDP/CBP | 3 (5.0) | |
Preoperative intraperitoneal chemotherapy, n (%) | ||||
DDP/CBP | 6 (7.0) | DDP/NDP/LBP | 9 (15.0) | |
DDP + 5-FU | 3 (3.5) | PEM + DDP | 1 (1.7) | |
DTX + DDP/CBP | 2 (2.3) | |||
Postoperative intravenous chemotherapy, n (%) | ||||
PEM + DDP/CBP | 49 (57.0) | PEM + DDP/CBP | 26 (43.3) | |
GEM + DDP/CBP/OXA | 19 (22.1) | GEM + DDP/CBP/OXA | 5 (8.3) | |
PTX + DDP | 6 (7.0) | PEM | 4 (6.7) | |
Postoperative intraperitoneal chemotherapy, n (%) | ||||
PEM + DDP/CBP | 23 (26.7) | DDP | 12 (20.0) | |
DDP/CBP/OXA | 19 (22.1) | PEM + DDP/CBP | 8 (13.3) | |
DTX | 5 (5.8) | |||